Literature DB >> 16157401

Randomized clinical trial on continuous 7-days-a-week postoperative radiotherapy for high-risk squamous cell head-and-neck cancer: a report on acute normal tissue reactions.

Rafal Suwinski1, Magdalena Bankowska-Wozniak, Wojciech Majewski, Anna Sowa, Adam Idasiak, Ewa Ziolkowska, Wieslawa Windorbska, Rafal Tarnawski, Krzysztof Skladowski, Boguslaw Maciejewski.   

Abstract

BACKGROUND AND
PURPOSE: To analyse acute mucosal reactions in patients treated with continuous accelerated postoperative irradiation (p-CAIR) compared to conventionally fractionated postoperative radiotherapy (p-CF). PATIENTS AND METHODS: The patients were randomly assigned to receive 63 Gy in 1.8 Gy fractions 7-days-a-week given over a period of 5 weeks (n=88), or 63 Gy in 1.8 Gy fractions given 5-days-a-week over 7 weeks (n=87). It represents 65% of an overall trial size. Acute mucosal reactions were scored using modified Dische system. Polychotomous logistic regression was used to estimate the influence of the selected variables on maximum grade of mucositis, and percent of the body weight loss during radiotherapy.
RESULTS: The average maximum Dische score and percent of the patients with confluent mucositis were higher in patients treated with p-CAIR, compared to p-CF (13.3 vs. 10.8 and 54 vs. 27%). Polychotomous logistic regression analysis revealed that fractionation scheme and tumour site have significantly influenced maximum Dische score. Tumour site (laryngeal vs. other) had even stronger influence on maximum Dische score than fractionation scheme. The average residual Dische score 8 weeks after radiotherapy was higher in p-CAIR compared to p-CF (2.1 vs. 1.4), and was, most frequently, related to persistent mucosal erythema (70 vs. 57% of pts.). No severe consequential toxicity of radiotherapy was observed, so far, in the trial.
CONCLUSIONS: While the incidence, intensity and duration of mucosal reactions was higher in p-CAIR than in p-CF the accelerated treatment can be considered tolerable with respect to acute toxicity. In both arms of the trial slight or moderate mucosal erythema was the most frequent acute side effect, which did not completely subside within 8 weeks after irradiation.

Entities:  

Mesh:

Year:  2005        PMID: 16157401     DOI: 10.1016/j.radonc.2005.07.007

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  5 in total

1.  Randomized clinical trial on seven-day-per-week continuous accelerated irradiation for patients with esophageal carcinoma: preliminary report on tumor response and acute toxicity.

Authors:  Su-Ping Sun; Ya-Zhou Liu; Tao Ye; Wen Zhang; Wen-Bin Shen; Jing-Lei Shi; Hai-Ting Xu; Wei-Dong Wang
Journal:  World J Gastroenterol       Date:  2006-11-21       Impact factor: 5.742

Review 2.  Interventions for the treatment of oral cavity and oropharyngeal cancer: chemotherapy.

Authors:  Ambika Parmar; Michaelina Macluskey; Niall Mc Goldrick; David I Conway; Anne-Marie Glenny; Janet E Clarkson; Helen V Worthington; Kelvin Kw Chan
Journal:  Cochrane Database Syst Rev       Date:  2021-12-20

3.  Randomized clinical trial on 7-days-a-week post-operative radiotherapy vs concurrent post-operative radiochemotherapy in locally advanced cancer of the oral cavity/oropharynx: a report on acute normal tissue reactions.

Authors:  Rafal Suwinski; Grzegorz Wozniak; Maciej Misiolek; Magdalena Jaworska; Maciej Kozaczka; Wieslaw Bal; Elzbieta Nowara; Leszek Miszczyk
Journal:  Br J Radiol       Date:  2016-03-02       Impact factor: 3.039

4.  Soft Tissue Necrosis in Head and Neck Cancer Patients After Transoral Robotic Surgery or Wide Excision With Primary Closure Followed by Radiation Therapy.

Authors:  Yun Hee Lee; Yeon Sil Kim; Mi Joo Chung; Mina Yu; So Lyung Jung; Ie Ryung Yoo; Youn Soo Lee; Min Sik Kim; Dong Il Sun; Jin Hyung Kang
Journal:  Medicine (Baltimore)       Date:  2016-03       Impact factor: 1.889

5.  Accelerated vs. conventionally fractionated adjuvant radiotherapy in high-risk head and neck cancer: a meta-analysis.

Authors:  Christiane Matuschek; Jan Haussmann; Edwin Bölke; Stephan Gripp; Patrick J Schuler; Bálint Tamaskovics; Peter Arne Gerber; Freddy-Joel Djiepmo-Njanang; Kai Kammers; Christian Plettenberg; Bahar Anooshahr; Klaus Orth; Wilfried Budach
Journal:  Radiat Oncol       Date:  2018-10-04       Impact factor: 3.481

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.